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Background: Estimated glomerular filtration rate (eGFR) formulas are routinely used in human
patients to provide a more accurate evaluation of GFR compared to serum creatinine concentra-
tion alone. Similar formulas do not exist for cats.
Objectives: To validate a prediction formula for eGFR in cats based on adjusting serum creati-
nine concentration.
Animals: Client-owned cats with various levels of renal function.
Methods: The study was cross-sectional. Glomerular filtration rate was determined by iohexol
clearance. Variables including signalment, biochemical markers, and noninvasive measurements
considered to represent surrogate markers of muscle mass were evaluated with the reciprocal
of serum creatinine concentration in a multivariable regression model. The derived eGFR for-
mula was subsequently tested in another group of cats and agreement with GFR assessed.
Results: The formula was developed in 55 cats. Only a single morphometric measurement (pel-
vic circumference) along with the reciprocal of serum creatinine concentration (creatinine−1)
independently predicted GFR in the final multivariate model. The derived eGFR formula was
0.408 + (243.11 × creatinine−1 [μmol/L]) - (0.014 × pelvic circumference [cm]). When the for-
mula was tested in another 25 cats it was not found to offer any advantage over creatinine−1
alone in its relationship with GFR (eGFR, R2 = 0.44, P < .001 vs reciprocal of creatinine,
R2 = 0.45, P < .001). Furthermore, agreement between eGFR and GFR was poor.
Conclusions and Clinical Importance: An eGFR formula for cats that adjusted serum creatinine
concentration for a marker of muscle mass was developed. The formula did not provide a reli-
able estimate of GFR, and therefore, its routine use cannot be recommended.
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1 | INTRODUCTION
Detection of chronic kidney disease (CKD) before development of
azotemia in cats is desirable because implementation of therapeutic
interventions at this stage may delay or prevent progression of CKD.
Limitations of serum creatinine and urea concentrations and urine
specific gravity for assessing renal function, particularly in early stage
CKD, are recognized.1 Measurement of glomerular filtration rate
(GFR) is considered to provide the most accurate estimation of renal
function. Serum creatinine concentration is the most routinely used
Abbreviations: BCS, body condition score; BL, body length; BSA, body surface
area; BW, body weight; CKD, chronic kidney disease; CKD-EPI, chronic kidney
diseases epidemiology collaboration; eGFR, estimated glomerular filtration rate;
ECFV, extracellular fluid volume; FFM, fat free mass; FM, fat mass; FLH, fore-
limb height; GFR, glomerular filtration rate; HLH, hindlimb height; LFLC, left
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marker of GFR, but it not only reflects renal function but also other
factors including muscle mass. Creatinine is generated endogenously
from creatine and creatine phosphate in skeletal muscle cells. There-
fore, methods that correct plasma creatinine concentration for a
patient's muscle mass may give a more accurate estimation of GFR.
Estimated GFR (eGFR) formulas offer the advantage of more
accurately reflecting actual GFR than serum creatinine concentration
in human patients. By incorporating demographic and clinical variables
that may affect physiological processes contributing to serum creati-
nine concentration, a more accurate measurement of renal function
may be ascertained. Of most relevance are factors that contribute to
muscle mass such as age, sex, and race. It is now mandatory for eGFR
to be reported with every serum creatinine concentration measure-
ment performed in human patients in several states in the United
States, in the United Kingdom, and in Australia,2 highlighting the
importance of such formulas. The most widely used prediction formu-
las for GFR in human patients are the Cockcroft-Gault,3 Modification
of Diet in Renal Disease (MDRD),4 and Chronic Kidney Disease Epide-
miology Collaboration (CKD-EPI) formulas5 (Table 1). These formulas
estimate GFR from serum creatinine concentration by means of pre-
diction equations that take into account of factors such as age, sex,
race, and body size.3–5 After introduction of reporting of eGFR along-
side serum creatinine concentration, recognition of CKD by doctors
has increased.6
Identifying useful methods that correct serum creatinine concen-
tration to account for muscle mass would be important in developing
an eGFR formula for cats. Methods to directly measure muscle mass
cannot be readily applied to clinical patients.7 Skeletal muscle mass is
the largest component of fat-free mass (FFM) reported to be
0.49 × FFM in human patients.8 Determination of FFM therefore may
provide an estimate of muscle mass. In addition, morphometric mea-
surements, body condition score (BCS), and body weight (BW) also
may provide surrogate markers of muscle mass. A formula to predict
FFM in cats based on BW (kg) and various morphometric measure-
ments has been reported (Finch et al., J Vet Intern Med. 2010; 24:
1548 [abstract]).
No published eGFR formulas have been developed for veterinary
species and such a formula may prove to be a more useful indicator of
renal function than serum creatinine concentration alone. Our objec-
tives were to develop an eGFR formula in cats with various levels of
renal function based on noninvasive measurements including
signalment, morphometric measurements, FFM, and predicted FFM
by which to adjust serum creatinine concentration. A second objective
was to test the formula in another group of cats.
2 | MATERIALS AND METHODS
2.1 | Study population
Client-owned cats with various levels of renal function were recruited
into the study, but cats with evidence of concurrent medical disease
such as hyperthyroidism were excluded. Only cats with stable renal
function determined by at least 2 repeated serum creatinine concen-
tration measurements within 12 months in nonazotemic cats and
within 3 months in azotemic cats before GFR measurement were
included in the study. Cats with evidence of acute kidney injury were
excluded from the study. The cats were identified from an ongoing
cohort study conducted at 2 London-based first opinion practices
(Beaumont Sainsbury Animals' Hospital [BAH], Royal Veterinary Col-
lege, Camden and People's Dispensary for Sick Animals [PDSA], Bow).
The cats in this study were presented for senior cat wellness screen-
ing. At each visit, a full medical history was obtained, physical exami-
nation performed, urine sample collected by cystocentesis, blood
pressure measured by the Doppler technique and blood collected for
hematology, biochemistry and total serum thyroxine concentration
measurement. This approach allowed cats to be followed longitudi-
nally during which time some develop azotemic CKD and some
remained nonazotemic. Cats had no evidence of relevant clinical dis-
ease. Informed consent was obtained from the owners and the study
was conducted with approval from the Royal Veterinary College's
ethics and welfare committee.
2.2 | Measurement of GFR
Food was withheld for 12 hours before performing the measure-
ments. Glomerular filtration rate was determined by a previously
described iohexol clearance method.9 Briefly, a bolus dose of iohexol
(Omnipaque 300 [647 mg/mL; 300 mg of iodine/mL, GE Healthcare,
Wauwatosa, Wisconsin) was administered IV (1 mL/kg). Blood sam-
ples were collected at 120, 180, and 240 minutes postinjection.
Iohexol concentrations were determined at an external commercial
laboratory by a high performance liquid chromatography (HPLC)
TABLE 1 Estimated GFR (eGFR) formulae in human patients
Predicted clearance Formula Variable
Cockcroft-gault Creatinine clearance [(140 - age) × BW/f] × SCr Age (yrs), BW; body weight (kg), SCr; serum
creatinine (mg/L), f; factor 7.2 for males and 8.5
for females
MDRD 125I-Iothalamate
clearance
170 × SCr−0.999 × age-0.176 × 0.762
(if female) × 1.18
(if black) × SUN−0.170 × alb0.318
SCr; serum creatinine (mg/dL), age (yrs), SUN;
serum urea nitrogen (mg/dL), alb; serum
albumin (g/dL)
CKD-EPI 125I-Iothalamate
clearance
a × (SCr/b)c × 0.993age a is a factor based on race and sex (black women -
166, black men - 163, white women -
144, white men - 141), b is a factor based on
sex (women - 0.7, men - 0.9), c is a factor based
on sex and SCr (μmol/L; women SCr < 62 -
−0.329, SCr > 62 - −1.209, men SCr < 80 -
−0.411, SCr > 80 - −1.209), age (yrs)
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method (Epsom and St Helier University Hospital NHS trust, Epsom,
United Kingdom). Clearance was determined as dose/area under the
curve (AUC) where AUC was the area under the plasma concentration
vs time curve determined by a 1-compartment model. A previously
validated cat-specific correction formula for slope-intercept clearance
was applied to correct for the 1-compartment assumption.9 In addi-
tion, serum creatinine, urea, albumin, and total protein concentrations
were determined from a sample collected at the same time as GFR
measurement.
2.3 | Development of eGFR formula
The following variables were considered for inclusion in a multivari-
able regression model to predict eGFR: age, sex (categorized as either
male neutered or female neutered), breed (categorized as either
domestic short hair/long hair or pedigree), urea, albumin, total protein,
BW, BCS, predicted muscle mass, various morphometric measure-
ments, FFM, and predicted FFM. Body condition score was deter-
mined by a previously validated 9-point scaling system.10 Fat-free
mass was calculated by the equation11:
FFM¼Total body water TBWð Þ=0:74
where TBW was calculated by an 18-Oxygen (18O) dilution method
(Finch et al., J Vet Intern Med. 2010; 24: 1548 [abstract]). Briefly, base-
line blood samples and samples collected after an equilibration period
of 2 hours after administration of 18O (0.3 g/kg 10% solution H2
18O)
were analyzed at an external laboratory (Institute of Child Health,
London) by isotope ratio mass spectrometry (IRMS). Dilution space of
18O was calculated by the standard equation12:
Dilution space 18O¼ T ×A
a
×
δa– δtð Þ
δs– δpð Þ
where T is the mass of tap water diluent in which a is diluted, A is
dose of 18O administered, a is portion of dose administered of 18O
that was retained for mass spectrometer analysis, and δa, δt, δs, and δp
are isotopic enrichment in delta units of the portion of dose adminis-
tered, tap water diluent, postdose serum sample, and predose serum
sample, respectively. Delta units express isotopic enrichment relative
to 2 standard waters (standard mean ocean water and standard light
arctic precipitate). Total body water then was calculated as:
18O dilution space=1:01
where 1.01 is the correction factor to correct for 1% over-exchange
with nonaqueous compartments.
Predicted muscle mass was determined by the equation13:
Predicted muscle mass¼0:468×BW0:99
Morphometric measurements were performed with a flexible tape
measure and recorded to the nearest 0.1 cm. The same investigator
performed the measurements in all cats to minimize interobserver var-
iability. Cats stood in a standard position when measurements were
obtained. The following morphometric measurements were recorded
(Figure 1): left and right forelimb circumference (FLC) measured 3 cm
proximal to the carpus, left and right hindlimb circumference (HLC)
measured 3 cm proximal to the tarsus, left and right proximal hindlimb
circumference (PHLC) measured 1 cm proximal to the patella, thoracic
circumference (TC) measured at the level of the xiphoid process, pel-
vic circumference (PC) measured at the level of the ilium, body length
(BL) measured from nose tip to sacrococcygeal joint, forelimb height
(FLH) measured from ground to the dorsal border of scapula, and hin-
dlimb height (HLH) measured from ground to the dorsal border of
pelvis.
Predicted FFM was calculated by the equation (Finch et al., J Vet
Intern Med. 2010; 24: 1548 [abstract]):
Predicted FFM = −0.164 + (0.41 × BW) + (0.054 × FLH) + (0.098 ×
RFLC) - (0.028 × HLH)
where BW is body weight (kg), FLH is forelimb height (cm), RFLC
is right forelimb circumference (cm), and HLH is hindlimb height (cm).
Statistical analyses were performed by a statistical software pack-
age (SPSS version 17.0). Data were assessed for normality by the
Kolmogorov-Smirnov test and by visual inspection of graphical plots.
Data between the population in which the formula was developed
and that in which it was tested was compared by the Student's t test.
Where assumptions of linearity and Gaussian distribution were not
met, transformations were performed. Univariable linear regression
analysis was performed for each individual variable initially. Variables
with a P < .2 were entered into a manual forward stepwise linear
regression model containing the reciprocal of the serum creatinine
concentration to predict eGFR. The reciprocal of the serum creatinine
concentration was selected because it displayed a linear relationship
to GFR compared to that of serum creatinine concentration, which
was nonlinear. Predicted GFR was expressed as mL/min/kg. Model
assumptions and performance were evaluated by examining multicolli-
nearity, standardized residuals, Cook's distances, leverage values, and
by performing the Durbin-Watson test. Significance was set
at P < .05.
FIGURE 1 Diagram of a cat illustrating the morphometric
measurements recorded. Morphometric measurements were
determined using a flexible tape measure and determined to nearest
0.1 cm. BL - body length, FLC - forelimb circumference, HLC -
hindlimb circumference, FLH - forelimb height, HLH - hind limb
height, PC - pelvic circumference, PHLC - proximal hindlimb
circumference, TC - thoracic circumference
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2.4 | Testing of eGFR formula
The derived eGFR formula was subsequently applied to an additional
25 cats in which GFR assessed by iohexol clearance had been deter-
mined and performance tested by assessing the coefficient of deter-
mination (R2). Agreement was assessed by creating Bland-Altman
plots.14
3 | RESULTS
3.1 | Development of the eGFR formula
Data regarding signalment, renal function, and body composition are
included in Table 2. The following variables were significant in the uni-
variable analysis: reciprocal of serum creatinine concentration
(P < .001), serum urea concentration (P < .001), left forelimb circum-
ference (P = .019), and right proximal hindlimb circumference
(P = .047; Table 3).
Except for the reciprocal of serum creatinine concentration, vari-
ables describing signalment and serum parameters (listed in Table 3)
were not predictive of GFR in the final multivariable regression model.
Fat-free mass estimated by the cat prediction formula also was not
predictive of GFR. Only a single morphometric measurement
remained significant in the model to predict GFR with the reciprocal
of serum creatinine concentration. Three cats were excluded from the
final regression model because they did not meet the model assump-
tions. The final model used to develop the formula therefore included
52 cats. The derived eGFR formula was:
eGFR = 0.408 + (243.11 × creatinine−1 [μmol/L]) - (0.014 × PC [cm])
The model R2 was 0.67 (P < .001) and explained additional varia-
tion over the reciprocal of serum creatinine concentration alone
(R2 = 0.64, P < .001).
3.2 | Testing of the eGFR formula
Data regarding signalment, BW, and renal function are included in
Table 2. The mean  SD PC was not significantly different between
the development and test population (P = .141, 41.0  7.1, and
38.5  6.7 cm, respectively). Agreement between GFR and eGFR was
considered poor based on the wide limits of agreement
(−1.15-0.57 mL/min/kg). The negative bias (−0.29 mL/min/kg) also
indicated that eGFR underestimated GFR (Figure 2). The mean per-
cent error in 25 cats in which the eGFR formula for cats was tested
was −13.6%. The relationship between GFR and eGFR and GFR and
the reciprocal of serum creatinine concentration is presented in
Figure 3. The eGFR formula showed no advantage over the reciprocal
TABLE 2 Clinical data relating to population of cats in which the eGFR was developed and the population of cats in which the eGFR formula was
tested. Continuous variables are presented as mean  SD. FN - female neutered, MN - male neutered, DSH/DLH - domestic short hair/domestic
longhair
eGFR formula development
population (n = 55)
eGFR formula testing
population (n = 25)
P
value
Age (yrs) 12.8  3.2 12.4 3.7 .626
Sex FN n = 27
MN n = 28
FN n = 13
MN n = 12
.830
Breed DSH/DLH n = 40
Pedigree n = 15
DSH/DLH n = 17
Pedigree n = 8
.885
GFR (mL/min/kg) 1.54  0.57 1.87  0.56 .016
Serum creatinine concentration (μmol/L) 154.15  50.55 155.89  52.86 .941
Reciprocal of serum creatinine concentration
(μmol/L)
0.007  0.002 0.007  0.002 .925
Serum urea concentration (mmol/L) 12.02  3.80 12.28  4.00 .895
USG 1.046  0.022 1.039  0.021 .200
Body weight (kg) 4.42  1.14 4.20  1.31 .463
Body condition score (1-9) 6  1 5  1 .228
Fat-free mass (kg) 3.07  0.62 Not measured n/a
Predicted fat-free mass (kg) 3.05  0.59 3.02  0.71 .909
Predicted muscle mass (kg) 2.02  0.51 1.99  0.66 .824
Left forelimb circumference (cm) 8.29  0.94 7.91  0.96 .103
Right forelimb circumference (cm) 8.05  0.91 8.12  0.89 .621
Left hindlimb circumference (cm) 9.22  1.01 8.93  1.12 .242
Right hindlimb circumference (cm) 9.03  1.08 8.82  0.95 .416
Left proximal hindlimb circumference (cm) 24.60  4.04 23.30  2.80 .152
Right proximal hindlimb circumference (cm) 25.95  4.30 23.72  3.36 .026
Thoracic circumference (cm) 40.34  4.93 39.28  4.84 .378
Pelvic circumference (cm) 41.00  7.04 38.48  6.73 .141
Body length (cm) 53.30  5.14 53.28  2.71 .983
Forelimb height (cm) 26.70  3.13 36.93  3.04 .764
Hindlimb height (cm) 29.61  3.29 28.14  3.04 .062
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of serum creatinine concentration in its relationship with GFR (eGFR
R2 = 0.44, P < .001 vs reciprocal of serum creatinine concentration
R2 = 0.45, P < .001).
4 | DISCUSSION
In our study, the morphometric measurement, PC, was the only signif-
icant measurement considered to be a surrogate marker of muscle
mass for correcting the reciprocal of serum creatinine concentration
to predict GFR in a multivariable regression model. This eGFR formula
had a slightly stronger relationship to GFR (determined by iohexol
clearance) than the reciprocal of serum creatinine concentration in
cats in which the formula was developed (R2 = 0.67 vs R2 = 0.64).
However, when the formula was tested in an additional 25 cats, it was
not found to offer any improvement in predicting GFR than the recip-
rocal of the serum creatinine concentration alone (R2 = 0.44 vs
R2 = 0.45). Agreement of the eGFR formula with GFR was considered
poor based on the wide limits of agreement (−1.15-0.57 mL/min/kg)
and negative bias (−0.29 mL/min/kg).
Clinical concerns regarding accuracy of the eGFR formulas used
in humans in all patient populations along with the sensitivity and
specificity of the formulas have been expressed. The precision and
TABLE 3 Univariable analysis of predictors of GFR used to develop
an eGFR formula. Univariable analysis was performed in 55 cats.
Significant variables are highlighted in bold font
Variable R2 P value
Age 0.046 .115
Sex 0.059 .075
Breed 0.038 .154
Reciprocal of serum creatinine
concentration
0.437 <.001
Serum urea concentration 0.258 <.001
Serum albumin concentration 0.004 .631
Serum total protein concentration 0.017 .339
Body weight 0.053 .090
Body condition score 0.002 .749
Predicted muscle mass 0.037 .196
Fat-free mass 0.023 .318
Predicted fat-free mass 0.041 .151
Left forelimb circumference 0.099 .019
Right forelimb circumference 0.010 .472
Left hindlimb circumference 0.006 .560
Right hindlimb circumference 0.010 .464
Left proximal hindlimb circumference 0.053 .090
Right proximal hindlimb circumference 0.074 .047
Thoracic circumference 0.018 .330
Pelvic circumference 0.054 .089
Body length 0.048 .107
Forelimb height 0.005 .605
Hindlimb height 0.000 .970
FIGURE 2 Bland-Altman agreement plot showing agreement
between GFR (determined by iohexol clearance) and estimated GFR
(eGFR). Bold line represents bias (mean difference between GFR and
eGFR) and dashed lines represent upper and lower limits of
agreement (mean difference between GFR and eGFR 2 SD). The
bias indicated eGFR underestimated GFR and limits of agreement
were wide. Therefore, agreement was considered poor
FIGURE 3 (A) Relationship between GFR (determined by iohexol
clearance) and estimated GFR (eGFR). eGFR underestimated GFR.
Bold line is regression line for GFR and eGFR and dashed line is line of
equality.(B) relationship between GFR (determined by iohexol
clearance) and the reciprocal of serum creatinine concentration. Bold
line is regression line for GFR and the reciprocal of serum creatinine
concentration
1974 FINCH ET AL.
accuracy of the formulas are questionable, particularly in elderly
patients, patients with extremes of muscle mass, and in patients with
unstable renal function. Furthermore, the earlier formulas3,4 may
underestimate true GFR leading to misclassification of some patients
as having CKD. In human patients, the correlation coefficient (r)
between GFR and eGFR predicted by the Cockcroft-Gault formula
was 0.83 and mean percentage error (expressed as a percentage of
true GFR) was 35% in 95% of patients.3 In the study that developed
the MDRD formula, the R2 for true and predicted GFR was 0.9 and
percentage error was 28.4% in 90% of the population.4 The main dif-
ference between the 2 populations was that the MDRD formula
included a more diverse population and studied additional factors
such as age, sex, and ethnicity and included only patients with CKD.
The Cockcroft-Gault population did not include such a varied popula-
tion, was only developed in hospitalized males, and data regarding
whether any patients had CKD were not included. When the abbrevi-
ated MDRD formula was applied to CKD patients, the R2 was 0.79,
but in normal patients the R2 was only 0.19.15 Furthermore, mean per-
centage error was −6.2% in CKD patients and −29% in healthy
patients.15 The most recently developed prediction formula for GFR
in human patients is the CKD-EPI formula. Because this formula was
developed in patients with decreased and normal renal function, it is
considered appropriate for both populations. It is reported that
84.1% of patients had GFR estimates within 30% of true GFR, by this
formula.5 In our study, 68% of cats had an eGFR within 30% of GFR.
When the relationship between serum creatinine concentration and
GFR was explored in the study in which the MDRD equation was
developed, the R2 was 0.8 (vs 0.9 for GFR and eGFR),4 suggesting
these formulas do offer some advantage over the use of serum cre-
atinine concentration alone. However, it is clear from the mean per-
cent errors that the formulas are not particularly precise predictors
of GFR in humans. Mean percent error in 25 cats in which the eGFR
formula for cats was tested was −13.6%, which, interestingly, is con-
siderably lower than that obtained in some of the studies in humans.
An important conclusion from studies in humans that derived predic-
tion equations for GFR4,15 is that the population in which formulas
are developed should represent the target population. Our study
addressed this concern by inclusion of normal healthy cats and cats
with decreased renal function in development and testing of the
equation. It is disappointing that the eGFR formula for cats did not
appear to offer any advantage over measurement of the reciprocal
of serum creatinine concentration to predict GFR, which may reflect
the small number of cats included in the development of the formula.
Until a more accurate formula can be developed in a larger popula-
tion of cats, biomarkers such as serum creatinine or symmetric
dimethylarginine concentrations remain the best surrogate markers
of GFR in cats.
The primary source of creatinine generation is muscle mass. This
factor is addressed in human patients by including coefficients in GFR
prediction equations for factors affecting muscle mass such as age,
sex, and race. It is likely that there are important differences in creati-
nine generation in cats. It has been reported that serum creatinine
concentration is higher in Birman cats16 although whether this obser-
vation relates to lower GFR or increased creatinine generation is
unclear. Furthermore, chronic disease such as CKD can decrease
muscle mass, and therefore cats with chronic disease with the same
serum creatinine concentration as healthy cats will have lower GFR
if measured. This leads to a circular argument in which serum creati-
nine concentration or adjusted serum creatinine concentration is
used to predict GFR and determine if a patient has normal or abnor-
mal renal function, but CKD itself will affect serum creatinine con-
centration and hence also affect accurate estimation of renal
function by an eGFR formula. With this is mind, any eGFR formula
that is validated for cats should serve only as a screening test. In
addition, a useful eGFR formula should not only serve as a useful
screening test but also provide reliability and accuracy for monitor-
ing progression of CKD.
When using eGFR formulas it is important to ensure that identical
methods of analysis and the same laboratory are employed as those
used for deriving the formula. Differences in determination of serum
creatinine concentration, for example, if a method that detected non-
creatinine chromogens was used, would lead to errors in predicted
GFR. In studies of humans, differences in creatinine assays at different
clinical laboratories can cause errors in GFR estimation as high as
20%.17 Differences in serum creatinine concentrations determined at
different veterinary practices have been reported, making this factor a
relevant consideration in cats as well.18 Additionally, the same units of
measurement of creatinine must be required. The current formula was
derived by standard international (SI) units (μmol/L) and creatinine
concentrations reported in mg/dl would require conversion to μmol/L
before applying the formula.
The formula used to estimate FFM in our study does not predict
muscle mass. Skeletal muscle mass is the largest component of FFM
(reported to be 0.49 × FFM in human patients).8 No ratio has been
reported for cats. A method to determine skeletal muscle mass may
be important in cats because of its relationship with serum creatinine
concentration. In our study, it was not possible to measure muscle
mass directly and therefore predicted FFM was determined. The for-
mula for FFM in cats has been shown to provide good prediction of
true FFM determined from total body water and the hydration con-
stant in cats (Finch et al., J Vet Intern Med. 2010; 24: 1548 [abstract]).
In pediatric patients, correcting serum creatinine concentration for
body surface area or body mass index was not found to improve the
accuracy of GFR prediction.19 Further studies to explore the relation-
ships among muscle mass, serum creatinine concentration, and GFR
are required in cats. Larger studies performed in a more varied popula-
tion of cats to that included in our study may be needed before a reli-
able eGFR formula can be recommended. Doing so may involve direct
measurement of muscle mass rather than FFM, although this may be
difficult to achieve in clinical patients, and other factors such as sex,
age, breed and disease state may influence GFR and serum creatinine
concentration.
Development of an eGFR formula for cats to correct creatinine
for body composition in our study did not provide a reliable estimate
of GFR in cats, and therefore its routine use cannot be recommended.
Moreover, the formula does not appear to improve the accuracy of
predicting GFR over serum creatinine concentration. Therefore, deter-
mination of GFR will remain important in the early identification and
accurate assessment of the stage of CKD.
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